Literature DB >> 6159130

The effects of the antagonists of the renin-angiotensin system on cardiovascular response to lower-body subatmospheric pressure in the anaesthetized cat.

S A Adigun, D P Clough, J Conway, R Hatton.   

Abstract

1. Lower-body subatmospheric (negative) pressure led to a prompt reduction in central venous pressure and arterial blood pressure. Arterial blood pressure was then restored within 30 s and there was a tachycardia. These reflex responses have been used to investigate the role angiotensin plays in blood pressure control. 2. The initial plasma renin activity (2.9 ng of angiotensin I h-1 ml-1) did not change during the brief lowering of pressure. Before pressure was lowered neither the angiotensin-converting enzyme inhibitor nor a competitive antagonist, [Sar1, Ala8]-angiotensin II, lowered arterial pressure. 3. Nevertheless, after inhibition of the renin-angiotensin system by these agents, the reduction in blood pressure induced by lower-body negative pressure became greater and the blood pressure recovery was impaired. 4. The findings suggest that angiotensin, at a blood concentration which has no direct effect on blood pressure, interacts with the sympathetic nervous system to maintain arterial blood pressure.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159130     DOI: 10.1042/cs0580549

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  3 in total

Review 1.  Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.

Authors:  P A Van Zwieten; A De Jonge; P B Timmermans
Journal:  Pharm Weekbl Sci       Date:  1983-10-21

2.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

3.  Heart rate control in hypertensive patients treated by captopril.

Authors:  A Sturani; C Chiarini; E Degliesposti; A Santoro; A Zuccalà; P Zucchelli
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.